News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website

 

The efficacy of carmustine wafers (Gliadel) for older patients with glioblastoma multiforme: prolonging survival.


Posted on: 07/17/2011

Neurol Res. 2011 Sep;33(7):759-64.

The efficacy of carmustine wafers for older patients with glioblastoma multiforme: prolonging survival.

Chaichana KL, Zaidi H, Pendleton C, McGirt MJ, Grossman R, Weingart JD, Olivi A, Quiñones-Hinojosa A, Brem H.
Source
Department of Neurosurgery, The Johns Hopkins Neuro-Oncology Surgical Outcomes Research Laboratory, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
 
Abstract
OBJECTIVE: 
Peak incidence of glioblastoma multiforme (GBM) occurs in individuals aged 65 years and older. The goal was to evaluate the efficacy of carmustine wafers in prolonging survival for older GBM patients.
 
METHODS: 
One hundred and thirty-three consecutive patients aged 65 years and older who underwent surgery for an intracranial primary (de novo) GBM from 1997-2007 were retrospectively reviewed. Among these 133 patients, 45 patients with carmustine wafer implantation were matched with 45 patients without implantation. These groups were matched for factors consistently shown to be associated with survival (age, Karnofsky performance scale, extent of resection, radiation therapy, and temozolomide). Survival was expressed as estimated Kaplan-Meier plots, and log-rank analysis was used to compare survival curves. Variables with P<0·05 were considered statistically significant.
 
RESULTS: 
The mean (±standard deviation) age of the cohort was 73±5 years, and the median survival of the entire cohort was 5·9 months. Among patients with and without carmustine wafers, there were no significant differences in pre- and peri-operative variables. However, patients with carmustine wafers demonstrated prolonged survival as compared to patients without wafers. The median survival for patients with carmustine wafers was 8·7 months, while median survival for patients without wafers was 5·5 months (P=0·007). Likewise, in subgroup analysis, patients older than 70 years (P=0·0003) and 75 years (P=0·04) who had carmustine wafers had significantly longer survival than matched patients without wafers.
 
DISCUSSION: 
Older patients with GBM may benefit from carmustine wafers. The survival for older patients who received carmustine wafers is significantly longer than matched patients who did not receive carmustine wafers.
 
 PMID: 
21756557 [PubMed - in process] 
 

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740